G&S Capital’s GSK GSK Stock Holding History

G&S Capital’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-157	Closed	-$7K	–	227
2018 Q4	$7K	Buy	+157	New	+$7.73K	0.01%	166

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return

G&S Capital's GSK Position: Q1 2019 in Review

G&S Capital sold out of GSK (GSK) in Q1 2019, closing a stake of 157 shares — an estimated $7K sold.

G&S Capital first reported a position in GSK in Q4 2018 and held it in 1 quarter. The position peaked at $7K in Q4 2018. 847 funds tracked by Wall St. Rank hold GSK as of Q1 2019.

G&S Capital reported no remaining GSK position as of Q1 2019 after selling out during the quarter.
G&S Capital sold 157 GSK shares in Q1 2019, an estimated $7K.
G&S Capital first reported a position in GSK in Q4 2018 and held it in 1 quarter.
G&S Capital's GSK position peaked at $7K in Q4 2018.
847 funds tracked by Wall St. Rank held GSK as of Q1 2019.

Based on G&S Capital's 13F filing for Q1 2019, filed 22 Apr 2019.